Physician profile
Robert E Hunter
NPI 1104891431
$119,196.92
in general payments reported to CMS, 2019-2025
14 companies · $25K in 2025
The $25K reported for 2025 was more than what 92% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,814 · 2020: $2,592 · 2021: $9,198 · 2022: $26K · 2023: $25K · 2024: $28K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $79K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $78,549.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $113,261.50 | 2019-2025 | Microraptor, Biceptor |
| Gemini Mountain Medical, LLC | $2,937.96 | 2019-2022 | |
| Evolution Surgical, INC | $1,227.72 | 2022 | |
| Arthrex, INC. | $1,226.39 | 2019-2020 | |
| Pacira Therapeutics, INC. | $213.05 | 2019 | |
| Depuy Synthes Sales INC. | $61.76 | 2021-2022 | |
| Medical Device Business Services, INC. | $58.33 | 2022 | |
| Medtronic, INC. | $49.18 | 2022 | |
| Zimmer Biomet Holdings, INC. | $45.83 | 2020 | |
| Arthrosurface Incorporated | $33.33 | 2019 | |
| Bioventus LLC | $31.27 | 2021 | |
| Fx Shoulder Solutions, INC | $22.94 | 2019 | |
| Medacta USA, INC. | $16.66 | 2020 | |
| Acumed LLC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.